Leukemia

Investigators of a prospective study of 1253 patients find that outcomes with the experimental homoharringtonine-based regimen either meet or exceed those with a classic etoposide-based regimen.

Patients who are already enrolled on clinical trials assessing magrolimab in acute myeloid leukemia are eligible to continue treatment with the agent.

Findings from a real-world study highlight that treatment utilization, such as agents for managing tumor lysis syndrome, appears to be more intense when older patients with chronic lymphocytic leukemia initiate treatment with venetoclax plus obinutuzumab.

Data from a next-generation sequencing analysis indicate that XPO1 may be a novel biomarker predictive of a decreased time to first treatment in patients with early-stage chronic lymphocytic leukemia.

Naval G. Daver, MD, reviewed current treatment options in acute myeloid leukemia, specifically the use of menin inhibitors in the space.

Investigators will work with the FDA to assess the root cause of a grade 5 serious adverse effect in phase 2 PLAT-08 trial evaluating SC-DARIC33 in pediatric acute myeloid leukemia.

Following a review of data with low-dose dasatinib in chronic myeloid leukemia, key opinion leaders from the Mayo Clinic and UT Southwestern consider its role in real-world practice.

The experimental agent appears tolerable in patients with newly diagnosed FLT3-mutated acute myeloid leukemia in a phase 1b trial.

In the last presentation of the session, Abhishek Mangaonkar, MBBS, details clinical trial data with low-dose dasatinib in patients with chronic myeloid leukemia.

In this cross Q&A, both the Mayo Clinic and UT Southwestern teams share insight on the role of olverembatinib in relapsed/refractory chronic myeloid leukemia.

Closing out their discussion on relapsed/refractory chronic lymphocytic leukemia, key opinion leaders consider important takeaways from the indirect comparison study of acalabrutinib versus zanubrutinib and identify unmet needs in the treatment landscape.

Key safety data from the indirect comparison study of acalabrutinib versus zanubrutinib in patients with relapsed/refractory chronic lymphocytic leukemia.

Combined with chemotherapy, blinatumomab appears tolerable and beneficial in a subgroup of pediatric patients with B-cell acute lymphoblastic leukemia in first relapse but does not yield better survival outcomes in the overall population.

A comprehensive review of chronic myeloid leukemia olverembatinib data led by expert Kebede Begna, MD, from the Mayo Clinic team.

The potential reduction in relapse in patients with unresectable chronic lymphocytic leukemia appears to happen regardless of minimal residual disease status 3 months post-treatment and immunoglobulin heavy-chain variable region mutational status.

JZP458 is part of a multi-agent chemotherapy regimen for lymphoblastic lymphoma and acute lymphoblastic leukemia, and can be used for adult and pediatric patients.

Data from a phase 1b dose escalation and expansion study highlight an encouraging duration of remission using APVO436 plus venetoclax and azacitidine in patients with acute myeloid leukemia.

Data from the phase 3 QuANTUM-First trial support the FDA’s approval of quizartinib for managing FLT3-ITD–positive acute myeloid leukemia.

Findings from a phase 2 study may inform the design of future trials assessing fecal microbiota transplants in patients with acute myeloid leukemia.

Factors including measurable residual disease and CAR T-cell expansion appear to predict duration of response following JCAR014 in those with relapsed or refractory chronic lymphocytic leukemia in a phase 1/2 trial.

The agent will be evaluated in a phase 1 study for patients with several myeloid malignancies, in which investigators will identify a recommended phase 2 dose.

Pediatric patients with acute lymphoblastic leukemia and have KMT2A rearrangements were evaluated in a recent study published in the British Journal of Haematology.

A study regarding next-generation sequencing evaluated minimal residual disease in patients with acute myeloid leukemia.

The combination of venetoclax and ibrutinib may yield long-lasting treatment-free remission among patients with high-risk chronic lymphocytic leukemia.

Blinatumomab has been granted full approval by the FDA for patients with B-cell acute lymphoblastic leukemia and minimal residual disease of 0.01% or more.